Navigation Links
CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
Date:9/2/2009

VIENNA, Va., Sept. 2 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the elimination of Series K convertible notes (the "Notes"). The Notes, which had an initial principal value of $8.3 million, were issued in August 2006, and were convertible into common stock.

"The elimination of the Notes significantly strengthens the Company's balance sheet and removes a potential overhang for our shareholders," said Geert Kersten, CEL-SCI Corporation's Chief Executive Officer. "Over the past three months, we have considerably improved our financial condition, allowing us to move forward in the development of several of our promising clinical platforms."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CEL-SCI Completes $5.85 Million Registered Direct Offering
2. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
3. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
4. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
6. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
7. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
8. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
9. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... Angeles, CA (PRWEB) December 24, 2014 ... wreak havoc on those who have an intolerance to ... to diarrhea, gas, bloating, migraine headaches, joint pain and ... gluten free diet plans that deliver safe and ... certain foods that trigger a gluten allergy reaction. These ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... There’s a lot going on with The ... now in control of the Senate as well as the ... Act. A lawsuit has been brought against President Obama by ... the ACA have resulted in changes to the law without ... will take place to weigh the validity of subsidies provided ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... breathing disorders could face depression, says a study.// ... Wisconsin-Madison studied about 1,400 adults (aged 30-60) for up ... did not have breathing problems during sleep, those with ... times more likely to become depressed during the study, ...
... Anna Pou, during her first ever public appearance, since ... with dangerous injections, confirmed that neither she nor// the ... ,The charge labeled against them by the Louisiana ... second-degree murder. The witness account as mentioned in ...
... has revealed that exposure to high pollution levels can increase ... in Japan have found that the risk of stroke from ... ,Currently breathing and heart problems are associated with the ... hourly levels. ,The findings of the study ...
... (FDA) have approved a virus mix in spray form that ... month.// , ,Processed meats after being packaged get ... combination of viruses that kill this bacteria. Food companies can ... ,This virus mix is not effective against E. ...
... poor training is resulting in unnecessary emergency Caesarean births ... week’s British Medical Journal (BMJ) that expert obstetricians can ... UK, the decision whether to try a vaginal birth, ... Caesarean is taken in the delayed second-stage labor by ...
... A House committee on Wednesday passed a bill that will ... from the South and rural states said that// increased spending ... it is spreading. ,"It shouldn't matter where you ... care and therapy," said Rep. Joe Barton, R-Texas, chairman of ...
Cached Medicine News:Health News:Stroke Linked to High Pollution Levels 2Health News:Skilled Obstetricians to avoid unnecessary Caesareans 2
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Medicine Products: